AKRO Stock Cash Flow Statements

Akero Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Akero Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30

cash flows from operating activities
net income	-70,505,000	-70,725,000	-70,024,000	-72,705,000	-55,987,000	-53,344,000	-55,186,000	-39,659,000	-31,083,000	-25,831,000	-23,059,000	-35,542,000	-27,403,000	-26,029,000	-32,424,000	-24,330,000	-28,933,000	-15,090,000	-29,711,000	-21,403,000	-16,207,000	-11,886,000	-15,611,000	-15,554,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	9,055,000	8,784,000	7,176,000	7,468,000	7,656,000	7,398,000	6,116,000	5,739,000	4,798,000	4,844,000	4,040,000	11,731,000	4,161,000	3,311,000	2,642,000	2,612,000	2,436,000	2,364,000	1,916,000	1,546,000	1,323,000	1,237,000	670,000	483,000
depreciation			15,000	1,000	1,000	1,000	2,000	5,000	11,000	11,000	10,000	11,000	11,000	11,000	11,000
non-cash lease expense	68,000	66,000	65,000	64,000	62,000	62,000	60,000	59,000	58,000	57,000	55,000	55,000	54,000	53,000	52,000							54,000
net amortization of premiums and discounts on marketable securities	-2,860,000	-2,463,000
amortization of debt issuance costs and discount	186,000	178,000	174,000	164,000	157,000	112,000	120,000	116,000	112,000	100,000	94,000	94,000
fair value change in warrant liability	104,000	102,000	-9,000	39,000	-13,000	500,000	-39,000	8,000	-77,000	187,000	235,000
unrealized foreign exchange gain and loss			-86,000	86,000	3,000	-22,000	18,000	-6,000	5,000	-25,000	28,000	12,000	-15,000	-9,000	118,000
acquired in-process research and development expense			0	0
changes in operating assets and liabilities:
prepaid expenses and other assets	4,660,000	444,000	2,145,000	-13,761,000	-8,071,000	2,337,000	11,053,000	-17,421,000	133,000	-505,000	-545,000	535,000	-608,000	2,730,000	1,128,000	-381,000	-61,000	-2,787,000	3,161,000	4,880,000	-10,143,000	724,000	590,000	-1,794,000
accounts payable	2,392,000	1,811,000	-16,110,000	10,569,000	1,093,000	6,456,000	-4,229,000	1,339,000	2,876,000	-631,000	1,676,000	-853,000	2,392,000	-2,247,000	-196,000	4,590,000	-2,298,000	1,177,000	-1,208,000	2,100,000	1,001,000	588,000	854,000	-1,597,000
accrued expenses and other current liabilities	8,699,000	-5,791,000	12,644,000	1,454,000	157,000	4,344,000	-2,836,000	3,430,000	2,224,000	-1,872,000	-7,793,000	-645,000	1,887,000	-782,000	1,661,000	2,601,000	8,618,000	-4,143,000	2,305,000	-711,000	1,459,000	-1,931,000	1,952,000	5,250,000
operating lease liability	-71,000	-70,000	-68,000	-66,000	-63,000	-62,000	-60,000	-60,000	-75,000	-36,000	-55,000	-52,000	-50,000	-49,000	-48,000
net cash (used in) operating activities
cash flows from investing activities
purchase of short-term and long-term marketable securities	-75,676,000	-583,301,000	-79,728,000	-57,933,000	-339,407,000	-38,976,000	-58,214,000	-161,197,000
proceeds from maturities of short-term marketable securities	155,016,000	101,118,000	95,000,000	131,000,000	84,510,000	96,825,000	71,000,000	35,500,000	60,500,000	42,500,000	1,000	3,000,000	11,870,000	22,750,000	12,000,000	33,841,000	21,000,000	19,000,000	26,900,000	21,560,000	28,600,000	18,500,000
purchase of in-process research and development			0	0
net cash (used in) investing activities
cash flows from financing activities
proceeds from the exercise of stock options	2,975,000	7,396,000	8,242,000	3,131,000	3,000	1,769,000	450,000	806,000	1,555,000	456,000	2,787,000	2,082,000	0	147,000	114,000	219,000	393,000	24,000	19,000	163,000	9,000	112,000	30,000	0
proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases			140,000	0			83,000	0			102,000	0			158,000
proceeds from the issuance of common stock and pre-funded warrants in a follow-on public offering	0	378,350,000
proceeds from the issuance of common stock in a follow-on public offering			0
proceeds from the issuance of common stock pursuant to the atm offering	0	10,361,000	67,638,000	0	0	10,604,000	0	0
proceeds from loan payable			0	0	0	10,000,000	0	0	0	15,000,000	0	0
payment of debt and equity issuance costs	0	-576,000	-29,000	-64,000	-477,000	-274,000	-31,000	0
net cash from financing activities	3,433,000	395,531,000	75,991,000	3,067,000	-150,000	366,938,000	502,000	806,000	336,855,000	15,153,000	2,723,000	217,900,000	34,877,000	132,000	243,000	69,000	266,000	24,000	59,000	202,784,000	100,000	164,000	115,000	-1,607,000
net increase in cash and cash equivalents	34,527,000	-154,316,000
cash and cash equivalents at the beginning of the period	0	340,238,000
cash and cash equivalents at the end of the period	34,527,000	185,922,000
supplemental disclosures of cash flow information:
cash paid for interest	997,000	980,000	1,034,000	1,087,000	1,093,000	768,000	768,000	766,000	670,000	279,000	252,000
non-cash investing and financing information:
change in net unrealizable gain on marketable securities	-97,000	137,000	-1,155,000				776,000	-255,000			37,000	3,000	27,000	-3,000	-10,000	-8,000
warrant liability costs reclassified to additional paid-in equity on vested warrants issued			0	0	0	431,000	0	0	0	330,000
debt and equity issuance costs included in accounts payable and accrued expenses and other current liabilities			-8,000	-49,000	-416,000	480,000
net cash from operating activities		-67,664,000	-67,090,000	-70,424,000	-57,453,000	-35,140,000	-48,627,000	-49,719,000	-22,389,000	-24,632,000	-25,508,000	-24,624,000	-19,509,000	-22,876,000	-26,695,000	-14,606,000	-20,034,000	-18,346,000	-23,395,000	-13,508,000	-22,584,000	-11,317,000	-11,649,000
capex		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows		-67,664,000	-67,090,000	-70,424,000	-57,453,000	-35,140,000	-48,627,000	-49,719,000	-22,389,000	-24,632,000	-25,508,000	-24,624,000	-19,509,000	-22,876,000	-26,695,000	-14,606,000	-20,034,000	-18,346,000	-23,395,000	-13,508,000	-22,584,000	-11,317,000	-11,649,000
net (cash used in) provided by investing activities		-482,183,000
write-off of deferred offering costs							0	0	0	337,000
net cash from investing activities			15,272,000	73,067,000	-255,896,000	57,849,000	12,786,000	-125,697,000	-128,302,000	17,590,000	-101,445,000	3,000,000	11,870,000	22,750,000	12,000,000	21,934,000	-10,654,000	19,000,000	17,899,000	-59,844,000	38,465,000	-6,281,000
proceeds from the issuance of common stock pursuant to registered direct offering							0	0
proceeds from the issuance of common stock pursuant to private offering											0	0
net increase in cash, cash equivalents and restricted cash			24,173,000	5,710,000	-313,499,000	389,647,000	-35,339,000	-174,610,000	186,164,000	8,111,000	-124,230,000	196,276,000	27,238,000	6,000	-14,452,000			678,000	-5,437,000	129,432,000			-83,047,000	-14,819,000
cash, cash equivalents and restricted cash at the beginning of the period			0	0	0	234,207,000	0	0	0	249,881,000	0	0				0	0	187,390,000		0	0	64,848,000
cash, cash equivalents and restricted cash at the end of the period					-313,499,000	623,854,000	-35,339,000	-174,610,000	186,164,000	257,992,000	-124,230,000	196,276,000				7,397,000	-30,422,000	188,068,000		129,432,000	15,981,000	47,414,000
deferred offering costs reclassified to additional paid-in equity							0	0			0	0
net amortization of premiums and discounts on short-term investments				-3,737,000	-3,447,000	-2,922,000	-3,646,000	-3,269,000	-1,371,000	-1,268,000	-194,000	1,000	46,000	135,000	361,000							-103,000
stock options exercises included in other current assets
proceeds from the issuance of common in a follow-on public offering					0	344,839,000
change in net unrealizable loss on marketable securities					-182,000	-349,000
purchase of short-term marketable securities										-24,910,000					0	-11,907,000			-8,996,000	-81,260,000	0	-24,781,000
payment of loan payable issuance costs										-25,000	0	-140,000
payment of follow-on public offering issuance costs										-278,000
payment of deferred offering costs											-40,000	-30,000	-46,000	-15,000	-29,000
change in net unrealizable loss on short-term marketable securities										-16,000
deferred offering costs included in accounts payable and accrued expenses and other current liabilities										189,000	-8,000	0	0	15,000		-119,000
proceeds from the issuance of common stock in a follow-on public offering, net of underwriting costs											0
payment of private equity offering costs											0
equity issuance costs included in accounts payable and accrued expenses and other current liabilities											-78,000	154,000
supplemental disclosures of non-cash investing and financing information:
debt issuance costs included in accounts payable and accrued expenses and other current liabilities
cash, cash equivalents and restricted cash at the beginning of the year														150,591,000
cash, cash equivalents and restricted cash at the end of the year														150,597,000
other liabilities
proceeds from sales of short-term marketable securities
purchase of property and equipment
proceeds from the issuance of common stock in follow-on public offering, net of issuance costs and underwriting fees
proceeds from the issuance of common stock in initial public offering, net of issuance costs and underwriting fees
proceeds from the disgorgement of stockholders' short-swing profits																						52,000
proceeds from the early exercise of stock options in exchange for restricted common stock																							0	21,000

right of use asset obtained in exchange for operating lease liability
remeasurement of right of use asset and operating lease liability
conversion of convertible preferred stock into common stock																							0	0
rou asset obtained in exchange for operating lease liability
remeasurement of rou asset and lease liability																				0
net decrease in cash, cash equivalents and restricted cash																						-17,434,000
net unrealizable gain on marketable securities																		1,000	-19,000	-74,000	45,000	51,000
proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees																							0	-1,628,000
payment of initial public offering costs
shares issued in connection with amgen agreement
acquisition of technology in connection with amgen agreement
issuance date fair-value of anti-dilution liability
change in fair value of preferred stock tranche liability
change in fair value of anti-dilution right liability
proceeds from issuance of series a redeemable convertible preferred stock
proceeds from issuance of series b redeemable convertible preferred stock
payment of preferred stock issuance costs
cash and restricted cash at the beginning of the year
net unrealizable loss on marketable securities
accretion of redeemable convertible preferred stock to redemption value
issuance date fair value of preferred stock tranche obligation
settlement of future purchase obligation
issuance of series a redeemable convertible preferred stock in settlement of anti dilution right liability
extinguishment of call option liability
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
cash and restricted cash at beginning of period																								0
cash, cash equivalents and restricted cash at end of period																								-14,819,000
common stock issued in connection with amgen agreement

We provide you with 20 years of cash flow statements for Akero Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Akero Therapeutics stock. Explore the full financial landscape of Akero Therapeutics stock with our expertly curated income statements.

The information provided in this report about Akero Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.